City

Guangzhou (7)

Beijing (1)

Hangzhou (1)

Nanjing (1)

Shanghai (1)

Tianjin (1)

Zhenzhou (1)

Condition

Diffuse Large B Cell Lymphoma (7)

ALK-Positive Anaplastic Large Cell Lymphoma (2)

EBV-Positive DLBCL, Nos (2)

Follicular Lymphoma Grade IIIb (2)

High-grade B-cell Lymphoma (2)

Transformed Lymphoma (2)

Age Over 80 Years (1)

Follicular Lymphoma (1)

Lymphoma, Non-Hodgkin (1)

Overall Status

Recruiting (4)

Completed (1)

Not yet recruiting (1)

Unknown status (1)

Phase

phase 2 (3)

phase 1/phase 2 (2)

phase 3 (1)

Sponsor

Huiqiang Huang (2)

Guangdong Provincial People's Hospital (1)

Nanfang Hospital of Southern Medical University (1)

Shanghai CP Guojian Pharmaceutical Co., Ltd. (1)

Shanghai Ming Ju Biotechnology Co., Ltd. (1)

Sun Yat-sen University (1)

Collaborator

First People's Hospital of Foshan (1)

Guangzhou First People's Hospital (1)

Huizhou Municipal Central Hospital (1)

Shantou Central Hospital (1)

Intervention

apatinib (1)

camrelizumab (1)

cd19-targeted chimeric antigen receptor (car) t cells (1)

chop combined with cmab304 (1)

chop, cmab304 (1)

lenalidomide (1)

lenalidomide combined with rituximab (1)

r-chop protocol (1)

toripalimab, rituximab (1)

Study Documents

Intervention Type

drug (5)

biological (1)

Funder Type

Other (5)

Industry (2)

Study Type

Interventional (6)

Observational (1)

diffuse large b cell lymphoma

Showing NaN - NaN of 7

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED